Application of ⁶⁸Ga- and ¹⁷⁷Lu-Labeled FAP Inhibitor in Evaluation and Treatment of Cardiac Fibrosis After Myocardial Infarction

Abstract

⁶⁸Ga and ¹⁷⁷Lu-labeled fibroblast activation protein inhibitor (FAPI) have been introduced for the diagnosis and treatment of multiple malignant and non-malignant diseases. While several studies have examined the application of ⁶⁸Ga-FAPI in myocardial infarction (MI), research on the use of ¹⁷⁷Lu-FAPI for the treatment of MI is still scarce. In this study, we evaluated the effects of ⁶⁸Ga-FAPI and ¹⁷⁷Lu-FAPI in cardiac fibrosis after MI using permanent coronary artery ligation rat models. ⁶⁸Ga-FAPI-04 effectively targeted fibroblasts within the MI area. Rats treated with ¹⁷⁷Lu-FAPI-04 had a significant increase in left ventricular ejection fraction at 28 days post-MI, with no obvious kidney or liver toxicity. Magnetic resonance imaging and histological analysis revealed a reduced fibrotic area in the ¹⁷⁷Lu-FAPI group. ¹⁷⁷Lu-FAPI-04 exerted its therapeutic effect by suppressing activation and inducing apoptosis of fibroblasts. In summary, we demonstrated that ¹⁷⁷Lu-FAPI-04 could effectively target FAP and eliminate activated fibroblasts after MI, thereby contributing to the development of new strategies for the treatment of MI.

Keywords

cardiac fibrosis / ⁶⁸Ga-FAPI / ¹⁷⁷Lu-FAPI / myocardial infarction

References

[1] C. W. Tsao, A. W. Aday, Z. I. Almarzooq, et al., “Heart Disease and Stroke Statistics-2023 Update: A Report from the American Heart Association,” Circulation 147, no. 8 (2023): e93-e621.

[2] L. Li, Q. Zhao, and W. Kong, “Extracellular Matrix Remodeling and Cardiac Fibrosis,” Matrix Biology 68-69 (2018): 490-506.

[3] M. Liu, B. Lopez de Juan Abad, and K. Cheng, “Cardiac Fibrosis: Myofibroblast-Mediated Pathological Regulation and Drug Delivery Strategies,” Advanced Drug Delivery Reviews 173 (2021): 504-519.

[4] K. E. Porter and N. A. Turner, “Cardiac Fibroblasts: At the Heart of Myocardial Remodeling,” Pharmacology & Therapeutics 123, no. 2 (2009): 255-278.

[5] K. Maruyama and K. Imanaka-Yoshida, “The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress,” International Journal of Molecular Sciences 23, no. 5 (2022): 2617.

[6] M. Zhao, L. Wang, M. Wang, et al., “Targeting Fibrosis, Mechanisms and Cilinical Trials,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 206.

[7] S. W. van den Borne, J. Diez, W. M. Blankesteijn, J. Verjans, L. Hofstra, and J. Narula, “Myocardial Remodeling After Infarction: The Role of Myofibroblasts,” Nature Reviews Cardiology 7, no. 1 (2010): 30-37.

[8] M. R. Zile, C. F. Baicu, J. S. Ikonomidis, et al., “Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin,” Circulation 131, no. 14 (2015): 1247-1259.

[9] J. Tillmanns, D. Hoffmann, Y. Habbaba, et al., “Fibroblast Activation Protein Alpha Expression Identifies Activated Fibroblasts After Myocardial Infarction,” Journal of Molecular and Cellular Cardiology 87 (2015): 194-203.

[10] K. Dendl, S. A. Koerber, C. Kratochwil, et al., “FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?,” Cancers (Basel) 13, no. 19 (2021): 4946.

[11] M. Li, M. H. Younis, Y. Zhang, W. Cai, and X. Lan, “Clinical Summary of Fibroblast Activation Protein Inhibitor-Based Radiopharmaceuticals: Cancer and Beyond,” European Journal of Nuclear Medicine and Molecular Imaging 49, no. 8 (2022): 2844-2868.

[12] H. Venugopal, A. Hanna, C. Humeres, and N. G. Frangogiannis, “Properties and Functions of Fibroblasts and Myofibroblasts in Myocardial Infarction,” Cells 11, no. 9 (2022): 1386.

[13] Y. Mori, K. Dendl, J. Cardinale, C. Kratochwil, F. L. Giesel, and U. Haberkorn, “FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease,” Radiology 306, no. 2 (2023): e220749.

[14] B. Xie, J. Wang, X. Y. Xi, et al., “Fibroblast Activation Protein Imaging in Reperfused ST-Elevation Myocardial Infarction: Comparison With Cardiac Magnetic Resonance Imaging,” European Journal of Nuclear Medicine and Molecular Imaging 49, no. 8 (2022): 2786-2797.

[15] M. Totzeck, J. Siebermair, T. Rassaf, and C. Rischpler, “Cardiac Fibroblast Activation Detected by Positron Emission Tomography/Computed Tomography as a Possible Sign of Cardiotoxicity,” European Heart Journal 41, no. 9 (2020): 1060.

[16] D. Finke, M. B. Heckmann, E. Herpel, et al., “Early Detection of Checkpoint Inhibitor-Associated Myocarditis Using (68)Ga-FAPI PET/CT,” Frontiers in Cardiovascular Medicine 8 (2021): 614997.

[17] B. X. Chen, H. Q. Xing, J. N. Gong, et al., “Imaging of Cardiac Fibroblast Activation in Patients With Chronic Thromboembolic Pulmonary Hypertension,” European Journal of Nuclear Medicine and Molecular Imaging 49, no. 4 (2022): 1211-1222.

[18] B. M. Prive, M. A. Boussihmad, B. Timmermans, et al., “Fibroblast Activation Protein-Targeted Radionuclide Therapy: Background, Opportunities, and Challenges of First (Pre)Clinical Studies,” European Journal of Nuclear Medicine and Molecular Imaging 50, no. 7 (2023): 1906-1918.

[19] N. G. Frangogiannis, “The Extracellular Matrix in Ischemic and Nonischemic Heart Failure,” Circulation Research 125, no. 1 (2019): 117-146.

[20] R. Kalluri, “The Biology and Function of Fibroblasts in Cancer,” Nature Reviews Cancer 16, no. 9 (2016): 582-598.

[21] R. Schuster, J. S. Rockel, M. Kapoor, and B. Hinz, “The Inflammatory Speech of Fibroblasts,” Immunological Reviews 302, no. 1 (2021): 126-146.

[22] Y. Luo, Q. Pan, H. Yang, L. Peng, W. Zhang, and F. Li, “Fibroblast Activation Protein-Targeted PET/CT With (68)Ga-FAPI for Imaging IgG4-Related Disease: Comparison to (18)F-FDG PET/CT,” Journal of Nuclear Medicine 62, no. 2 (2021): 266-271.

[23] M. J. Livingston, S. Shu, Y. Fan, et al., “Tubular Cells Produce FGF2 via Autophagy After Acute Kidney Injury Leading to Fibroblast Activation and Renal Fibrosis,” Autophagy 19, no. 1 (2023): 256-277.

[24] Z. Varasteh, S. Mohanta, S. Robu, et al., “Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a (68)Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04,” Journal of Nuclear Medicine 60, no. 12 (2019): 1743-1749.

[25] H. Kaur, M. Takefuji, C. Y. Ngai, et al., “Targeted Ablation of Periostin-Expressing Activated Fibroblasts Prevents Adverse Cardiac Remodeling in Mice,” Circulation Research 118, no. 12 (2016): 1906-1917.

[26] K. E. Oatmen, E. Cull, and F. G. Spinale, “Heart Failure as Interstitial Cancer: Emergence of a Malignant Fibroblast Phenotype,” Nature Reviews Cardiology 17, no. 8 (2020): 523-531.

[27] B. Hinz and D. Lagares, “Evasion of Apoptosis by Myofibroblasts: A Hallmark of Fibrotic Diseases,” Nature Reviews Rheumatology 16, no. 1 (2020): 11-31.

[28] M. Xu, J. Chen, P. Zhang, et al., “An Antibody-Radionuclide Conjugate Targets Fibroblast Activation Protein for Cancer Therapy,” European Journal of Nuclear Medicine and Molecular Imaging 50, no. 11 (2023): 3214-3224.

[29] Y. Liu, T. Watabe, K. Kaneda-Nakashima, et al., “Fibroblast Activation Protein Targeted Therapy Using [(177)Lu]FAPI-46 Compared With [(225)Ac]FAPI-46 in a Pancreatic Cancer Model,” European Journal of Nuclear Medicine and Molecular Imaging 49, no. 3 (2022): 871-880.

[30] Y. Sun, M. Ma, D. Cao, et al., “Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP,” Circulation Research 132, no. 5 (2023): 586-600.

[31] J. Milosevic, S. Hoffarth, C. Huber, and M. Schuler, “The DNA Damage-Induced Decrease of Bcl-2 Is Secondary to the Activation of Apoptotic Effector Caspases,” Oncogene 22, no. 44 (2003): 6852-6856.

[32] R. Singh, A. Letai, and K. Sarosiek, “Regulation of Apoptosis in Health and Disease: The Balancing Act of BCL-2 Family Proteins,” Nature Reviews Molecular Cell Biology 20, no. 3 (2019): 175-193.

[33] S. Ravassa, B. Lopez, T. A. Treibel, et al., “Cardiac Fibrosis in Heart Failure: Focus on Non-Invasive Diagnosis and Emerging Therapeutic Strategies,” Molecular Aspects of Medicine 93 (2023): 101194.

[34] J. G. Travers, C. A. Tharp, M. Rubino, and T. A. McKinsey, “Therapeutic Targets for Cardiac Fibrosis: From Old School to Next-Gen,” Journal of Clinical Investigation 132, no. 5 (2022): e148554.

[35] H. Tani, T. Sadahiro, Y. Yamada, et al., “Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction,” Circulation 147, no. 3 (2023): 223-238.

[36] J. G. Rurik, I. Tombacz, A. Yadegari, et al., “CAR T Cells Produced in Vivo to Treat Cardiac Injury,” Science 375, no. 6576 (2022): 91-96.

[37] E. W. Roberts, A. Deonarine, J. O. Jones, et al., “Depletion of Stromal Cells Expressing Fibroblast Activation Protein-Alpha From Skeletal Muscle and Bone Marrow Results in Cachexia and Anemia,” Journal of Experimental Medicine 210, no. 6 (2013): 1137-1151.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.